ADCTADC Therapeutics SA

CSNew York Stock Exchange (XNYS)·USD

Identity

Security key: 11309
Ticker: ADCT
Type: CS — Common Stock
Exchange: New York Stock Exchange(XNYS)
Venue group: NYSE
Operating MIC: XNYS
Market: stocks
Locale: us
Currency: USD
Listed: 2020-05-15
Round lot: 100
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: ADCT

Detail

Enriched 2026-08-14 20:47

Market cap: $156,445,124.34
Shares outstanding (class): 127,191,158
Shares outstanding (weighted): 127,191,158
SIC: 2834 PHARMACEUTICAL PREPARATIONS
Employees: 193
Location: EPALINGES, V8
Homepage: https://www.adctherapeutics.com
Description: ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Market cap and share counts drift.

Funds holding this security

51 funds · 51 positions · $41.59M reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
Eventide Healthcare & Life Sciences Fund MUTUAL FUND SERIES TRUST	—	$21.38M	1.35%	5,701,655 NS	TICKER
iShares Russell 2000 ETF iShares Trust	IWM	$9.22M	0.01%	2,458,561 NS	TICKER
iShares Russell 2000 Growth ETF iShares Trust	IWO	$3.11M	0.03%	830,092 NS	TICKER
iShares Biotechnology ETF iShares Trust	IBB	$2.52M	0.03%	673,142 NS	TICKER
iShares Micro-Cap ETF iShares Trust	IWC	$964.5K	0.08%	257,204 NS	TICKER
Master Small Cap Index Series Quantitative Master Series LLC	—	$650.1K	0.01%	173,365 NS	TICKER
SMALL COMPANY GROWTH PORTFOLIO VANGUARD VARIABLE INSURANCE FUNDS	—	$420.6K	0.03%	112,154 NS	TICKER
EQ/2000 Managed Volatility Portfolio EQ Advisors Trust	—	$391.4K	0.01%	104,376 NS	TICKER
Fidelity Small Cap Growth Index Fund Fidelity Salem Street Trust	—	$291.1K	0.03%	77,638 NS	TICKER
State Street(R) SPDR(R) S&P(R) International Sm… SPDR INDEX SHARES FUNDS	GWX	$289.8K	0.04%	77,293 NS	TICKER
VIP Disciplined Small Cap Portfolio Variable Insurance Products Fund II	—	$263.1K	0.05%	70,172 NS	TICKER
LVIP SSGA Small-Cap Index Fund LINCOLN VARIABLE INSURANCE PRODUCTS TRUST	—	$201.8K	0.01%	53,800 NS	TICKER
Small Cap Index Fund Northern Funds	—	$180.7K	0.01%	48,191 NS	TICKER
iShares Russell 3000 ETF iShares Trust	IWV	$177.8K	0.00%	47,405 NS	TICKER
STATE STREET SMALL/MID CAP EQUITY INDEX PORTFOL… STATE STREET INSTITUTIONAL INVESTMENT TRUST	—	$130.1K	0.00%	34,700 NS	TICKER

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

This match is a candidate, not a mapping. N-PORT tickers are filer-entered free text and collide with delisted and foreign symbols. Only 13% of positions carry a ticker at all. Good enough to ask which funds report holding a symbol; not good enough to build exposure reporting on. Prefer the ISIN-resolved link, which is marked FIGI_COMPOSITE.

Funds holding this security

Identifiers

master.security_identifier

TICKERADCT
CIK0001771910
ISINCH0499880968
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Biotechnology
Source: LLMunreviewed
Self-reported confidence: 0.95
Model: deepseek
Rationale: ADC Therapeutics is a biopharmaceutical company developing antibody-drug conjugates for oncology, fitting the biotechnology industry within healthcare.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.